Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HM 15912

Next Previous
X
Search
Drug Profile

HM 15912

Alternative Names: LAPSGLP-2 analog; HM-15912

Latest Information Update: 14 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class Glucagon-like peptides; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short bowel syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Short bowel syndrome

Most Recent Events

  • 15 Aug 2023 Hanmi Pharmaceutical completes the phase I trial in Short bowel syndrome (In volunteers, In adults, In the elderly) in USA (SC) (NCT05711381)
  • 15 Jun 2023 Pharmacodynamics data from a preclinical studies in Short bowel syndrome presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)
  • 02 Dec 2022 Phase-I clinical trials in Short bowel syndrome (In volunteers, In adults, In the elderly) in USA (SC) (NCT05711381)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top